{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:02:10Z","timestamp":1793253730016,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10928-025-09975-6","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T08:00:32Z","timestamp":1746864032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond the linear model in concentration-QT analysis"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6904-5569","authenticated-orcid":false,"given":"G\u00e9raldine","family":"Celli\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-976X","authenticated-orcid":false,"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8855","authenticated-orcid":false,"given":"Guillaume","family":"Bonnefois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1655-1113","authenticated-orcid":false,"given":"Jonathan","family":"Chauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"9975_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45:383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9975_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/psp4.12580","volume":"10","author":"E Briggs","year":"2021","unstructured":"Briggs E, Chapel S, Zhang P, Palmisano M, Tran JQ (2021) Concentration-QTc modeling of Ozanimod\u2019s major active metabolites in adult healthy subjects. CPT Pharmacomet Syst Pharmacol 10:119\u2013126. https:\/\/doi.org\/10.1002\/psp4.12580","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9975_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10928-012-9242-8","volume":"39","author":"P Grosjean","year":"2012","unstructured":"Grosjean P, Urien S (2012) Moxifloxacin versus placebo modeling of the QT interval. J Pharmacokinet Pharmacodyn 39:205\u2013215. https:\/\/doi.org\/10.1007\/s10928-012-9242-8","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9975_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00280-020-04204-y","volume":"87","author":"D Kang","year":"2021","unstructured":"Kang D, Ludwig E, Jaworowicz D et al (2021) Concentration\u2013QTc analysis of quizartinib in patients with relapsed\/refractory acute myeloid leukemia. Cancer Chemother Pharmacol 87:513\u2013523. https:\/\/doi.org\/10.1007\/s00280-020-04204-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"9975_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/0091270011416939","volume":"52","author":"JE Tisdale","year":"2012","unstructured":"Tisdale JE, Overholser BR, Wroblewski HA et al (2012) Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 52:1296\u20131305. https:\/\/doi.org\/10.1177\/0091270011416939","journal-title":"J Clin Pharmacol"},{"key":"9975_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10928-020-09728-7","volume":"48","author":"A Henrich","year":"2021","unstructured":"Henrich A, Juif PE, Dingemanse J, Krause A (2021) PK\/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. J Pharmacokinet Pharmacodyn 48:213\u2013224","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9975_CR7","doi-asserted-by":"publisher","first-page":"e01112","DOI":"10.1002\/prp2.1112","volume":"11","author":"M Anliker-Ort","year":"2023","unstructured":"Anliker-Ort M, Hsin C-H, Krause A et al (2023) Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist. Pharmacol Res Perspect 11:e01112. https:\/\/doi.org\/10.1002\/prp2.1112","journal-title":"Pharmacol Res Perspect"},{"key":"9975_CR8","doi-asserted-by":"publisher","first-page":"E609","DOI":"10.1208\/aapsj070363","volume":"7","author":"V Piotrovsky","year":"2005","unstructured":"Piotrovsky V (2005) Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT\/QTc prolongation. AAPS J 7:E609\u2013E624. https:\/\/doi.org\/10.1208\/aapsj070363","journal-title":"AAPS J"},{"key":"9975_CR9","unstructured":"Holford NHG, Karlsson MO (2008) A tutorial on visual predictive checks. 17th PAGE Meeting, Abstract 1434:1\u201317. http:\/\/www.page-meeting.org\/?abstract=1434"},{"key":"9975_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1214\/14-EJS890","volume":"8","author":"M Delattre","year":"2014","unstructured":"Delattre M, Lavielle M, Poursat MA (2014) A note on BIC in mixed-effects models. Electron J Stat 8:456\u2013475. https:\/\/doi.org\/10.1214\/14-EJS890","journal-title":"Electron J Stat"},{"key":"9975_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10928-020-09725-w","volume":"48","author":"G Ferber","year":"2020","unstructured":"Ferber G, Darpo B, Garnett C et al (2020) Detection and impact of hysteresis when evaluating a drug\u2019s QTc effect using concentration-QTc analysis. J Pharmacokinet Pharmacodyn 48:187\u2013202. https:\/\/doi.org\/10.1007\/s10928-020-09725-w","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9975_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF01061905","volume":"17","author":"P Girard","year":"1989","unstructured":"Girard P, Boissel JP (1989) Clockwise hysteresis or proteresis. J Pharmacokinet Biopharm 17:401\u2013402. https:\/\/doi.org\/10.1007\/BF01061905","journal-title":"J Pharmacokinet Biopharm"},{"key":"9975_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/cts.12640","volume":"12","author":"M Minocha","year":"2019","unstructured":"Minocha M, Li H, Chiu YL, Carter D, Othman AA (2019) Models of variability and circadian rhythm in heart rate, blood pressure, and QT interval for healthy subjects who received placebo in phase I trials. Clin Transl Sci 12:470\u2013480. https:\/\/doi.org\/10.1111\/cts.12640","journal-title":"Clin Transl Sci"},{"key":"9975_CR14","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1038\/psp.2013.71","volume":"3","author":"RN Upton","year":"2014","unstructured":"Upton RN, Mould DR (2014) Basic concepts in population modeling, simulation, and model-based drug development: part 3\u2014introduction to pharmacodynamic modeling methods. CPT Pharmacomet Syst Pharmacol 3:e88. https:\/\/doi.org\/10.1038\/psp.2013.71","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9975_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jad.2021.02.048","volume":"285","author":"Y Kim","year":"2021","unstructured":"Kim Y, Kim A, Chung JY (2021) Population pharmacokinetic\/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. J Affect Disord 285:120\u2013126. https:\/\/doi.org\/10.1016\/j.jad.2021.02.048","journal-title":"J Affect Disord"},{"key":"9975_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","volume":"74","author":"WS Cleveland","year":"1979","unstructured":"Cleveland WS (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829\u2013836. https:\/\/doi.org\/10.1080\/01621459.1979.10481038","journal-title":"J Am Stat Assoc"},{"key":"9975_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/01621459.1988.10478639","volume":"83","author":"WS Cleveland","year":"1988","unstructured":"Cleveland WS, Devlin SJ (1988) Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 83:596\u2013610. https:\/\/doi.org\/10.1080\/01621459.1988.10478639","journal-title":"J Am Stat Assoc"},{"key":"9975_CR18","unstructured":"Holford NH (2012) An introduction to visual predictive checks. http:\/\/holford.fmhs.auckland.ac.nz\/docs\/vpc-tutorial-and-datatop.pdf"},{"key":"9975_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716\u2013723. https:\/\/doi.org\/10.1109\/TAC.1974.1100705","journal-title":"IEEE Trans Autom Control"},{"key":"9975_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1214\/aos\/1176344136","volume":"6","author":"G Schwarz","year":"1978","unstructured":"Schwarz G (1978) Estimating the dimension of a model. Ann Statist 6:461\u2013464. https:\/\/doi.org\/10.1214\/aos\/1176344136","journal-title":"Ann Statist"},{"key":"9975_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jelectrocard.2021.01.004","volume":"65","author":"I Singh","year":"2021","unstructured":"Singh I, Rabkin SW (2021) Circadian variation of the QT interval and heart rate variability and their interrelationship. J Electrocardiol 65:18\u201327. https:\/\/doi.org\/10.1016\/j.jelectrocard.2021.01.004","journal-title":"J Electrocardiol"},{"key":"9975_CR22","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1111\/j.1540-8159.2005.00006.x","volume":"28","author":"B Sredniawa","year":"2005","unstructured":"Sredniawa B, Musialik-Lydka A, Jarski P, Kalarus Z, Polonski L (2005) Circadian and sex-dependent QT dynamics. Pacing Clin Electrophysiol 28:S211\u2013S216. https:\/\/doi.org\/10.1111\/j.1540-8159.2005.00006.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"9975_CR23","unstructured":"Simulations Plus. Monolix User Guide. https:\/\/monolixsuite.slp-software.com\/"},{"key":"9975_CR24","unstructured":"Simulations Plus. Simulx User Guide. https:\/\/monolixsuite.slp-software.com\/simulx\/"},{"key":"9975_CR25","unstructured":"Simulations Plus Lixoft connectors: R-package installation and initialization. https:\/\/monolix.lixoft.com\/monolix-api\/lixoftconnectors_installation\/"},{"key":"9975_CR26","unstructured":"R Core Team (2017) R: a language and environment for statistical computing. R Vienna, Austria: Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"key":"9975_CR27","unstructured":"Allaire JJ, Teague C, Scheidegger C, Xie Y, Dervieux C (2024) Quarto. https:\/\/cran.r-project.org\/web\/packages\/quarto\/"},{"key":"9975_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","volume":"96","author":"L Johannesen","year":"2014","unstructured":"Johannesen L, Vicente J, Mason JW et al (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 96:549\u2013558. https:\/\/doi.org\/10.1038\/clpt.2014.155","journal-title":"Clin Pharmacol Ther"},{"key":"9975_CR29","unstructured":"Johannesen L, Vicente J, Mason JW et al (2014) ECG Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine 1.0.0. Data set to Johannesen et al (2014). https:\/\/physionet.org\/content\/ecgrdvq\/1.0.0\/SCR-002.Clinical.Data.csv"},{"key":"9975_CR30","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol 2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"2","key":"9975_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10928-020-09725-w","volume":"48","author":"G Ferber","year":"2020","unstructured":"Ferber G, Darpo B, Garnett C, Huang D et al (2020) Detection and impact of hysteresis when evaluating a drug\u2019s QTc effect using concentration-QTc analysis. J Pharmacokinet Pharmacodyn 48(2):187\u2013202. https:\/\/doi.org\/10.1007\/s10928-020-09725-w","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9975_CR32","unstructured":"Simulations Plus. Vanoxerine C-QTc case study. https:\/\/monolix.lixoft.com\/case-studies\/vanoxerine-c-qtc-case-study\/"},{"key":"9975_CR33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/psp4.12286","volume":"7","author":"A K\u00fcmmel","year":"2018","unstructured":"K\u00fcmmel A, Bonate PL, Dingemanse J, Krause A (2018) Confidence and prediction intervals for pharmacometric models. CPT Pharmacomet Syst Pharmacol 7:360\u2013373. https:\/\/doi.org\/10.1002\/psp4.12286","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09975-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:31:05Z","timestamp":1757169065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9975"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09975-6","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees and\/or shareholders of Simulations Plus, Inc., the company developing and commercializing MonolixSuite. AK is a member of the editorial board of the Journal of Pharmacokinetics and Pharmacodynamics. The review process was conducted without his involvement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"31"}}